peptides for broken bone recovery: Frequently asked questions

No, but you've missed the inflammatory phase window where TB-500 has the strongest effect. Start BPC-157 immediately. Weeks 3–6 align with peak callus formation and angiogenesis, which is where BPC-157 demonstrates its clearest benefit. Research shows peptide administration during the reparative phase still accelerates healing even when the inflammatory phase has passed. Pair BPC-157 (200–500 mcg daily) with a GH secretagogue to support osteoblast activity during remodeling.

Age reduces baseline GH and IGF-1 levels, which slows fracture healing independent of peptide use. Elderly patients show 40–50% longer healing timelines than younger adults. GH peptides like MK-677 demonstrate the strongest effect in aging populations precisely because they restore IGF-1 to youthful ranges. A 2018 study in the Journal of Clinical Endocrinology & Metabolism found MK-677 (25 mg daily) increased bone mineral density by 7% over 12 months in participants aged 65+. Combine GH peptides with BPC-157 to address both the angiogenic deficit and the hormonal deficit simultaneously.

Weight-bearing bones require higher mechanical loading to stimulate osteoblast differentiation, but the cellular mechanisms peptides target remain the same. The difference is timeline. Femoral fractures naturally take 12–16 weeks to heal versus 6–8 weeks for smaller bones. BPC-157's angiogenic effect is particularly valuable in femoral fractures because the bone's thickness limits vascular penetration. A 2020 study in Bone found that fractures in long bones with compromised blood supply (smokers, diabetics) showed greater relative improvement with VEGF-targeting peptides compared to fractures in healthy individuals.

Consider BPC-157 as the primary intervention. Non-unions are most commonly caused by inadequate vascularization at the fracture site. Administer 200–400 mcg subcutaneously near the non-union daily for 4–6 weeks while maintaining mechanical stability with appropriate immobilization. The peptide's VEGF upregulation can restart the angiogenic phase that stalled initially. Combine with a bone stimulator if already prescribed. The two interventions address different bottlenecks (vascular vs mechanical signaling).

Age-related decline in bone healing is multifactorial. Reduced growth hormone, impaired angiogenesis, chronic low-grade inflammation, and decreased osteoblast activity. A combination protocol may be appropriate: TB-500 during the first two weeks to manage inflammation, then transition to BPC-157 for weeks 3–6 to support callus formation, finishing with GHK-Cu during months 2–4 to optimize remodeling. This sequential approach addresses the compounding deficits older patients face rather than relying on a single mechanism.

These bones have poor intrinsic blood supply, making them prone to delayed union. Use BPC-157 starting immediately post-injury. The earlier angiogenesis begins, the better. Dosing remains 200–400 mcg daily, subcutaneous administration as close to the fracture as anatomically feasible. The Jones fracture (fifth metatarsal base) has a non-union rate approaching 30% in athletes; preclinical data suggests BPC-157 could reduce that significantly, though human trials are still pending.